lenalidomide has been researched along with allopurinol in 3 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (allopurinol) | Trials (allopurinol) | Recent Studies (post-2010) (allopurinol) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 15,096 | 743 | 3,363 |
| Protein | Taxonomy | lenalidomide (IC50) | allopurinol (IC50) |
|---|---|---|---|
| Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | Rattus norvegicus (Norway rat) | 3.3765 | |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | 3.1861 | |
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | 5.0758 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 8.69 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
1 review(s) available for lenalidomide and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for lenalidomide and allopurinol
| Article | Year |
|---|---|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
1 other study(ies) available for lenalidomide and allopurinol
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |